13564 Background: Retrospective analyses on elderly people enrolled in clinical trials of
adjuvant chemotherapy for colon cancer indicated the maintenance of the efficacy in that …

Background It is common for elderly patients to be underrepresented in clinical trials for
cancer, which can result in a lack of efficacy data and unclear criteria to guide treatment …

Objective The aim of this prospective, single-arm phase II trial was to confirm the safety and
efficacy of neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX) …

Aim According to established guidelines, patients with Stage III colon cancer should receive
adjuvant chemotherapy. However, a significant proportion do not. This study assessed …

Background Elderly patients are frequently excluded from randomized trials. It is unclear if
adjuvant chemotherapy improves outcomes of colorectal cancer in such patients. The …

PURPOSE The phase III ACHIEVE trial conducted in Japan was one of six prospective
studies included in the International Duration Evaluation of Adjuvant Therapy collaboration …

BACKGROUND Controversy exists regarding adjuvant oxaliplatin treatment among older
patients with stage II and III colorectal cancer (CRC). This study sought to identify …

Background 5-fluorouracil (5-FU) was the standard treatment care for colorectal cancer
(CRC), however, its efficacy was limited due to safety concerns. Capecitabine and …

Purpose An oxaliplatin-based regimen is the most common adjuvant chemotherapy for
patients with stage II/III colorectal cancer, but many patients experience dose reduction or …

4024 Background: Consideration of metastasectomy is now standard practice in the
management of selected patients (pts) with stage IV MCRC. As a result, modification to the …